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Introduction: The International Society of Paediatric Oncology (SIOP) protocols recommend
preoperative chemotherapy appropriate for Wilms tumors (WTs) in children with renal tumors
aged ≥6 months, reserving biopsy for “atypical” cases. The Children's Cancer and Leukaemia
Group (CCLG) joined the SIOP-WT-2001 study but continued the national practice of biopsy at
presentation.
Method: Retrospective study of concordance between locally reported renal tumor biopsies and
central pathology review nephrectomy diagnoses of children enrolled by CCLG centers in the
SIOP-WT-2001 study.
Results: Biopsy reports were available for 552/787 children with unilateral tumors. 36 of
552 (6.5%) were nondiagnostic: 2 normal tissue, 12 necrotic, 9 insufficient sample, and
13 indeterminate results (disproportionately non-WTs). The sensitivity and specificity of biopsy to
identify tumors that did not require SIOP empirical preoperative chemotherapy were 86.0% and
99.6%, respectively. 13 of 548 (2.4%) biopsy results were discordant with nephrectomy; non-WTs
other than renal cell carcinoma and clear cell sarcoma of the kidney (CCSK) were poorly recog-
nized. In children aged 6-119 months, 480 of 518 (91.6%) had WT or nephroblastomatosis. 5 of
518 (1%) had benign tumors, and only one diagnosed on biopsy. Biopsy results correctly changed
clinical management in 25 of 518 (4.8%), including identifying 19 of 20 CCSKs, but would have
led to overtreatment in 5 of 518 (1%) or undertreatment in 4 of 518 (0.8%). In children aged ≥10
years, biopsy correctly changedmanagement in 5 of 19 (26%) cases with no discordance.
Conclusion: Biopsy is less effective at identifying non-WTs thanWTs and rarely changes manage-
ment in younger children. Biopsy should be reserved in SIOP protocols for children≥10 years and
in younger children with clinical or radiological features inconsistent withWT.
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1 INTRODUCTION
Renal tumors represent 7% of pediatric cancers, with Wilms tumor
(WT) the most common, accounting for about 90% of renal cancers
in European Cancer registries.1,2 WT has a median age of diagnosis
of 3 years and generally has a good prognosis with 5-year overall
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in anymedium, provided
the original work is properly cited.
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survival 93% and 2-year event-free survival 87%.3 Non-WTs are rare
in children and predominantly include mesoblastic nephroma (MN),
clear cell sarcoma of the kidney (CCSK), rhabdoid tumor of the kidney
(RTK), and renal cell carcinoma (RCC). MN is a tumor of lowmalignant
potential usually requiring no further treatment than nephrectomy. It
is themost common renal tumor amongneonates but after 3months of
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age,MN represents fewer than 10% of renal tumors,4 and in total 75%
allMNs in theUKoccur under the age of 6months.5 CCSKhas a similar
age distribution to WT but requires more intensive chemotherapy to
achieve similar 5 year outcomes compared with WT.6,7 RTK typically
presents in the first 1-2 years and has a considerably poorer prognosis,
despite more intensive chemotherapy, with median survival less than
1 year.8 RCC typically presents in adolescence, is chemotherapy
resistant, and requires effective surgical clearance, with molecular
targeted therapy used in appropriate cases.
There are two philosophies for the initial management of pediatric
renal tumors. The Children's Oncology Group (COG) protocols advo-
cate upfront nephrectomy to achieve an accurate tissuediagnosis prior
to postoperative chemotherapy. The International Society of Paedi-
atric Oncology (SIOP) Renal Tumour Study Group (SIOP-RTSG) pro-
tocols use preoperative chemotherapy to minimize the risk of preop-
erative tumor rupture, give a more favorable stage distribution, and
to allow histological response to chemotherapy to be included in risk
stratification of postoperative treatment.9,10 Upfront nephrectomy is
advocated only for children under 6 months of age where there is a
much higher incidence of tumors that do not require cytotoxic treat-
ment. There are no significant differences in overall survival between
concurrent COG and SIOP renal tumor trials.3
The UK and Irish Children's Cancer and Leukaemia Group (CCLG)
changed from immediate nephrectomy to a preoperative chemother-
apy approach when they joined the SIOP WT 2001 trial after the
UKW3 trial compared the two approaches.11 However, we continued
using percutaneous biopsy (PCNB) prior to commencing chemother-
apy in all cases to reduce the risk of giving inappropriate chemother-
apy to children with non-WTs. For other countries participating in the
SIOP WT 2001 trial, biopsy was not recommended routinely but only
permitted when there was clinical diagnostic uncertainty.
Biopsy carries risks that may not outweigh the clinical benefits of
identifying non-WTs, especially in the age range whereWT is the most
likely diagnosis. The largest study of pediatric biopsy associated mor-
bidity in 182 cases enrolled in UKW3 found 19% of patients suffered
pain, 7% infection, and 5% postprocedure bleeding.12 A further con-
cern is that biopsy poses a risk of local tract seeding, but only a few
cases are reported in the literature.13,14 Large adult series (>10,000
patients) suggest needle track recurrence occurs in <0.01% cases15
comparedwith 0.5% in the above pediatric series.12 In the UKW3 trial,
biopsy was not significantly associated with risk of local relapse in
multivariate analysis.16
In this study, we analyzed the diagnostic accuracy of locally
reported biopsies compared to the central pathology review (CPR)
nephrectomy diagnoses, and assessed the implications of any discor-
dancy for the clinical effectiveness of a policy of universal renal biopsy
for pediatric renal tumors by age group.
2 METHODS
A retrospective study of children enrolled through the CCLG in the
SIOPWT2001 trial.10 Childrenwere eligible for inclusion if they had a
unilateral renal tumor that had been biopsied at presentation. Biopsy
TABLE 1 Grouping of tumors according to how a correct diagnosis
on biopsy would have changed initial management
Group Description Tumors included


















Clear cell sarcoma of the kidney
Rhabdoid tumor of the kidney
Anaplastic sarcoma











nephrogenic rests that have
imaging appearances of a
proliferating tumor
SIOP-RTSG, International Society of Paediatric Oncology Renal Tumour
Study Group.
was recommended using a 12-14G cutting needle under ultrasound
guidance andwith consideration of using a coaxial technique.
The pathology reports of renal tumor biopsies were obtained retro-
spectively fromparticipatingCCLGcenters by requesting toprovide all
biopsy reports for the children they had enrolled, and trial case files of
G. Vujanic (Chair of the CCLG Pathology Panel) for biopsies that were
sent for CPR (note that biopsies were not required to be sent routinely
for CPR). Biopsies were reported locally prior to nephrectomy.
Each local pathology report was coded by a nonpathologist (TJJ)
into one of 15 categories (Supporting Information File S1) and the type
of the biopsy (fine needle aspirate, PCNB or open) was recorded based
on the description in the report. Five of the categories were consid-
ered as types of “nondiagnostic”: “normal renal tissue,” “necrotic sam-
ple,” “insufficient sample,” “indeterminate diagnosis,” and “indetermi-
nate diagnosis—not a WT.” A case was classed as “indeterminate” if
the pathologist offered a differential diagnosis or stated they were
not confident of a single diagnosis. The full local pathology report of
all cases classified as “indeterminate diagnosis” was reviewed by an
expert pediatric pathologist (GMV).
The CPR nephrectomy diagnoseswere extracted from the SIOPUK
WT 2001 trial and study database held at the Cancer Research UK
Clinical Trials Unit, University of Birmingham.
Patients were divided into four clinically meaningful groups to
assess the ability of biopsy to correctly identify cases, which would
require a different management than the standard SIOP preoperative
chemotherapy approach3 (Table 1). Group A comprised benign tumors
for which chemotherapy is unnecessary, Group B comprised RCCs,
Group C comprised other malignant tumor types requiring more
intensive chemotherapy regimens (mainly CCSK and RTK), Group
D comprised WT and hyperplastic nephrogenic rests that would be
treated appropriately by the standard SIOP chemotherapy. A binary
classification sensitivity-specificity analysis was performed comparing
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Group D versus those that required alternative management (Groups
A-C). Data are presented as a 3×2 contingency table as recommended
by Simel.17 The worst-case sensitivity was defined as treating all
Groups A-C cases with a biopsy that was nondiagnostic or indeter-
minate and included WT in the differential as false negatives and the
worst case specificity as treating nondiagnostic/indeterminate biop-
sies in Group D cases as false positives: the analysis used a modified
version of the “intention to diagnose” approach18 based on the inten-
tion to discriminate between WT and non-WT. Overall concordance
between first biopsy and subsequent nephrectomy diagnosis was
assessed. A more detailed assessment within each clinically relevant
groupwas then performed as some discordant results would not result
in incorrect management.
Subgroup analyses were performed for three specific age groups:
the first were children under the age of 6 months, for whom upfront
nephrectomy is already advised, the second between 6 months and 9
years and 11 months, and the third group children aged 10 years or
over, where the relative incidence of non-WTs starts to increase.
Analyses were performed in the R statistical environment19 with
graphical output produced using ggplot2.20 Exact binomial 95%
confidence intervals (CI) were calculated for sensitivity, specificity,
nondiagnostic, and accuracy estimates.
3 RESULTS
3.1 Inclusion
There were 849 cases enrolled by 25 centers (22 UK, 1 Irish, 1 Aus-
tralian, 1 NewZealand) into the CCLG database for the SIOPWT2001
trial, fromMarch 2002 to December 2011. The upper age limit for this
trial was 18 years. We excluded 62 children with bilateral (stage V)
disease, 64 cases with upfront nephrectomy, and 169 cases without a
biopsy report either because a biopsywas not performed or the report
was not provided by the recruiting center (19 centers provided copies
of original biopsy reports). In one case, biopsy of a metastatic site was
used for primary diagnosis. One child had tumor rupture associated
with biopsy, therefore an emergency nephrectomy was performed
without local reporting of the biopsy material. Of the remaining 552
cases, there were three cases where the pathology panel could not
give a definitive diagnosis and one child died prior to nephrectomy.
Accordingly, 548 cases were included in the concordance analysis
(Supporting Information Figure 1). A histogram showing the relative
distribution of different tumors types in children of different ages
enrolled in the trial is presented in Figure 1, with the biopsy population
showing a similar distribution (Supporting Information Figure 2).
There was no significant difference in the proportion of non-WTs for
cases where a biopsy report was obtained compared to where it was
not (49/548 vs 12/163, Fisher's exact test, P= 0.633)
3.2 Type of biopsy
Of the 552 initial biopsies, 541 were PCNB, 10 open, and in one case
the type of biopsy could not be determined from the pathology report
andwasmissing from the registration case report form.
F IGURE 1 Stacked histogram for the age at presentation for all
unilateral cases. Bin width= 2months
3.3 Nondiagnostic and indeterminate biopsy results
Thirty-six of 552 (6.5%; 95% CI, 4.6-8.9%) biopsies were nondiagnos-
tic; two had only normal renal tissue, 12werewholly necrotic, and nine
were an insufficient sample. Thirteen reportswere considered indeter-
minate by a pathologist, of which two had a differential diagnosis that
only included non-WTs. A biopsy was repeated in seven of 36 cases, of
which six were diagnostic (five WTs and one neuroblastoma). Patients
with indeterminate biopsies were more likely to have a final diagnosis
in Groups A-C than Group D—six of 49 (12.2%) versus seven of 539
(1.3%) (Fisher's exact test, P = 0.00029). However, there was no such
difference for biopsies that were nondiagnostic because of procedure
failure (sampling normal tissue, necrotic regions or having an insuffi-
cient sample)—two of 49 (3.9%) versus 21 of 539 (4.1%) (Fisher's exact
test, P= 1.00).
3.4 Sensitivity analyses
The overall sensitivity of biopsy to identify tumors that needed alter-
native treatment from the recommended preoperative treatment for
WT was 86.0% [95% CI, 72.0-94.7%], with a specificity for biopsy
correctly identifying WT/NR of 99.6% [95% CI, 98.4-99.9%]. The
worst-case sensitivitywas 75.5% [95%CI, 61.1-86.7%] andworst-case
specificity 94.0% [95%CI, 91.5-95.9%] (Figure 2).
3.5 Concordance
The concordance between biopsy and nephrectomy is detailed in Sup-
porting Information File S3. Counting allWT subtypes as one category,
biopsywas discordant in 13 of 548 (2.4%) cases and fully concordant in
499of548 (91.1%). This gives anoverall accuracyof 499of512 (97.5%,
95%CI, 95.7-98.6%) for a diagnostic sample.
A discordant biopsy result was recorded for eight of 49 (16.3%) of
the non-WT compared with five of 499 (1.0%) in Group D (WT/NRs).
One of the Groups A-C cases with a discordant biopsy was an anaplas-
tic sarcoma of the kidney, which at the time of presentation was not a
4 of 7 JACKSON ET AL.
F IGURE 2 3 × 2 contingency table for the sensitivity and specificity
of biopsy to distinguish “Groups A-C tumors” (i.e., those that do not
require the standard pre-operative SIOP regimen) fromGroupD
tumors (that do). “Worst case” calculations are on an intention to
diagnose principle. Far right panel corresponds to definitions of each
square in the 3 × 2 grid: TP, true positive; TN, true negative; FP, false
positive; FN, false negative; NDP, nondiagnostic positive;
NDN, nondiagnostic negative
recognized entity in the literature so a pathologist could not have been
expected to recognize it. Three of the five discordant cases in Group
D were nephrogenic rests diagnosed as WT on biopsy (which cannot
easily distinguish these two entities and their initial management usu-
ally includes the same preoperative chemotherapy used forWT). After
accounting for the two caveats above, there remains a statistically sig-
nificant difference in discordance rate between Groups A-C and D
(7/48; 14.6% vs 2/499; 0.4%, Fisher's exact test, P= 5.0 × 10−7).
The concordance between biopsy diagnosis and nephrectomy
based on clinically relevant groups is summarized in Table 2 and as
follows:
Group A: Five of nine (55.6%) benign tumors were cor-
rectly identified on biopsy with two nondiagnostic cases. Of
the remaining two of nine cases with discordance between
biopsy and final nephrectomy, one was reported as CCSK on
biopsy but was an MN on nephrectomy, and the other was a
cystic partially differentiated nephroblastoma (CPDN) diag-
nosed asWT on biopsy.
Group B: Eight of 10 (80%) RCCs were correctly identi-
fied and the other two biopsies suggested an alternative
diagnosis (one as aWT and one as a metanephric adenoma).
Group C: Twenty of 30 (66.7%) other malignant non-WTs
were correctly identified, 19 of these were cases of CCSK,
which accounted for two-thirds of all cases inGroupC. In four
cases, a biopsy suggested a diagnosis ofWTwith the ultimate
nephrectomyhistologyRTK in two cases and one case each of
anaplastic sarcoma and desmoplastic small round cell tumor
(DSRCT).
Group D: This was the largest group, consisting of WT (495
cases) and nephrogenic rests (four cases). In 20 cases (4.0%),
the biopsy failed to provide diagnostic material and in three
of four cases diagnosed as nephrogenic rests on the nephrec-
tomy specimen, the initial biopsy suggested WT. Anaplasia
was not reported in 27 of 30 (90%) of adequate biopsies from
children with diffuse anaplastic WT. Overall, in 466 of 499
(93.4%) cases, the biopsy correctly identified WT/NR, both
appropriate for preoperative chemotherapy with vincristine
and actinomycin D. In two of 499 (0.4%) cases, the biopsy
suggested an alternative malignant histology (one CCSK and
one RTK).
3.6 Subgroup analyses
Cases were subgrouped based on the different age distributions of
tumors. In the age range at which WT is commonest (6-119 months
group), 10 of 518 (2%) children had tumors requiring only surgery (five
benign tumors and five RCCs) compared with five of 19 (26.3%) chil-
dren aged 10 years and over (all RCCs). Similarly, 480 of 518 (92.6%)
cases of tumors in children aged 6-119 months were Group D (i.e., no
management change required) versus 12 of 19 (63.2%) cases of tumors
in theolder age group. Comparedwith thewhole cohort, the sensitivity
of biopsy to identify Groups A-C (non-WT) in children 6-119months is
reduced to 82.4% (95% CI, 65.5-93.2%) with worst-case sensitivity of
73.7% (95%CI, 56.9-86.6%) (Figure 3).
3.7 Clinical implications
Overall, 37 of 548 (6.7%) children had a non-WT and the biopsy
identified a diagnosis that required a change from the standard
SIOP preoperative chemotherapy management (“clinical effective-
ness”). Furthermore, six cases of non-WTwere not detected by biopsy
and 28 cases of WT/NR had nondiagnostic biopsies (Table 3 and
Supporting Information File S2).
The biopsy result would have changed management for 28 for
518 children (5.4%) in the 6-119 months group (24 were correctly
TABLE 2 Summary of the concordance between biopsy and nephrectomy for all cases, grouped according to how a correct biopsy diagnosis










Concordant biopsy 5 8 20 466
Discordant biopsy 2 2 4 5
Nondiagnostic result 2 0 6 28
Total 9 10 30 499
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F IGURE 3 3 × 2 contingency table for the sensitivity and specificity
of biopsy to distinguish “non-Group D tumors” in children aged
greater than or equal to 6months but less than 10 years. Format is the
same as shown in Figure 2
diagnosed—19 CCSK, one DSRCT, three RCC, one benign tumor—with
one RCC misdiagnosed as a metanephric adenoma, an MN thought to
be CCSK, and two malignant tumors where WT was excluded but the
diagnosis was uncertain) compared with five of 19 (26%) children in
the 120 months+ group (all RCCs). In the 6-119 months group, five of
518 (1%) children with discordant biopsy results would have resulted
in overtreatment (one MN, one CPDN, two WT, and one RCC). Four
of 518 children would be undertreated (one anaplastic sarcoma, one
DSRCT, and two RTK). There were no cases of discordant results in the
120 months+ group (Table 3 and Supporting Information File 2). Five
of 518 (1%) children in the 6-119months group had benign lesions not
requiring chemotherapy, of which only onewas correctly identified.
4 DISCUSSION
This is the largest study of the diagnostic accuracy of pediatric renal
tumor biopsy. In addition to calculating estimates of concordance and
nondiagnostic rates, we also report on how effective biopsy (per-
formed by PCNB in 98% of cases) is in identifying tumors that require
a change inmanagement from the standard SIOP approach.
The overall concordance between biopsy and final nephrectomy
(91.7%) is slightly lower than the 94% figure found in Vujanic et al's
study fromUKW3.12 However, Vujanic et al's studyonly included cases
where both the biopsy and nephrectomywere sent forCPRand somay
represent a biased subgroup analysis. This suggests that where biopsy
is performed, CPRmay help improve diagnostic accuracy, as is the case
for nephrectomy specimens.21
We found that 6.5% of all biopsies were nondiagnostic, which is
slightly higher than the 4% figure found in the UKW3 study,12 but not
dissimilar to a pooled estimate of 6% for biopsy inadequacy from a sys-
tematic review of PCNB of pediatric tumors.22 Importantly, we report
the rates of different types of nondiagnosis. “Invalid” nondiagnostic
results, whereby the test procedure fails to provide material required
for diagnosis (“insufficient sample,” “wholly necrotic tissue,” “normal
renal tissue”), are different from valid nondiagnostic results (where
the procedure was adequate but there was diagnostic uncertainty—an
“indeterminate result”) as the latter may provide some clinically useful
information (e.g., this is a malignant neoplasm that is not a WT, but it
is not clear which non-WT).23 While PCNB alone may lead to unrep-
resentative material (an invalid non-diagnostic result), this risk is min-
imized by using an image-guided coaxial technique to sample material
from themost suspicious areas of the tumor.24
Note that 36% of the nondiagnostic results in this study were inde-
terminate results. It is unclear whether this was because pathologists
were less certain of the diagnosis or more prepared to admit diagnos-
tic uncertainty in SIOP UK 2001 than UKW3 or whether the differ-
ent researchers in each paper classified pathology reports differently.
For example, the degree of diagnostic certainty associated with identi-
cal phraseology can be interpreted differently between surgeons and
pathologists.25
The SIOP approach is to treat all pediatric renal tumors (unless they
are completely cystic on imaging studies or occur in children under 6
months of age or clinical features are atypical) with empirical preop-
erative chemotherapy appropriate for the most likely diagnosis ofWT.
Hence, the potential utility of biopsy is to correctly identify non-WTs











6-119months 120months+ 6-119months 120months+ 6-119months 120months+ 6-119months 120months+
Correct diagnosis 1 0 3 5 20 0 448 12
Discordant diagnosis—
appropriate treatment
0 0 1 0 0 0 2 0
Discordant diagnosis—VA
would be “over treatment”
2 0 1 0 0 0 2 0
Discordant diagnosis—VA
would be “under treatment”
0 0 0 0 4 0 0 0
Nondiagnostic 2 0 0 0 4 2 28 0
Total 5 0 5 5 28 2 480 12
Groups are as described in Table 1, according to how a correct biopsy diagnosis could have changedmanagement.
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to permit an early change in management. However, the sensitivity of
biopsy to identify these tumors is considerably poorer than the speci-
ficity to avoid misdiagnosis of WT. There were also higher levels of
diagnostic uncertainty with non-WT cases. Identification of high-risk
tumors that require chemotherapy other than CCSK was particularly
poor (although these cases, such as RTK and DSRCT, are a minority of
all high-risk tumors).
Our data suggest that overall biopsy would be expected to cor-
rectly change management in 6.7% cases. If we confine the analysis to
the 6-119 months age group and include CCSK in the group that are
considered to be adequately treated by vincristine and actinomycin-
D preoperative chemotherapy, this drops to six of 518 (1.2%) cases.
This is a reasonable analysis as although there are no trials compar-
ing the different regimens for CCSK, there are no survival differences
between the UK (where the CCLG advocates AVD preoperatively if a
CSSK is identified) and Germany, where biopsy is rarely employed and
thus an AV regimen is de facto used or between SIOP andNWTS/COG
approaches.26
Ultimately, thepercentageof cases inwhichbiopsywill changeman-
agement is lower than the incidence of procedural complications pre-
viously reported.12 Our data suggest that biopsy in children over 6
months is not effective in avoiding unnecessary chemotherapy in chil-
dren with benign tumors but it is clearly effective in identifying RCCs
(an important diagnosis to make to avoid unnecessary chemotherapy
and allow timely surgical resection). Based on European population
based registry data, RCC accounts for 34%of all renal cancers in 10-14
years old compared with 4.3% in 5-9 years old butWT is still the most
common diagnosis in both age groups.2 We find using a cut-off of 10
years and above increases the clinical effectiveness of biopsy to 26%,
with all cases of RCC being correctly identified. Comparing the distri-
bution of histological diagnoses of cases registered in the trial with the
national cancer registry of England confirms the suitability of this age
threshold for our population (Supporting Information Figure 3). Fur-
thermore, recent reviews of the use of PCNB in adult RCC suggest that
this technique is safe and provides adequate diagnostic information to
guide subsequent surgical management.27
There are some limitations of this study. First, we achieved partial
capture of the intended cohort as some centers did not respond to
requests to provide biopsy reports. Some patients from nonrespond-
ing centers were included as they also had biopsies sent for CPR. If
pathologists were more likely to send diagnostically challenging cases
for CPR, this may have increased the nondiagnostic rate. Second, this
study was confined to cases recruited to a trial focused on WT, hence
benign tumors may be underrepresented and some tumor types that
also occur in nonrenal sites were registered in other trials. As such,
the estimates of concordance are not fully generalizable to all pediatric
renal tumors. Third, changes in pathological practice over the last 15
years, such as the use of specific immunohistochemistry and molecu-
lar biology techniques to distinguish between different non-WTs, may
mean that the nondiagnostic and discordance rates may be overesti-
mated compared to current practice. As the use of CPR is associated
with increased diagnostic accuracy,21 our estimates cannot be applied
to situations where biopsies are subject to CPR. We used the local
biopsy reports as it was not part of the trial protocol for biopsies to
be sent routinely for CPR (unlike all nephrectomies). Some biopsies
were sent for CPR concurrently with the nephrectomy specimens and
sowere not blinded. Fourth, our estimates for clinical effectiveness are
inferred from the biopsy data rather than the actual treatment deci-
sions made locally. In practice, a biopsy result is always taken in the
context of imaging results and the child's clinical picture. Finally, our
resultsmaynot be generalizable to contextswhere biopsy is usedmore
selectively.
In summary, this study provides estimates for the diagnostic accu-
racy and clinical utility of pediatric renal tumor biopsy in the context of
a preoperative chemotherapy approach. Our results suggest that for
children aged under 10 years, biopsy is unlikely to change clinical man-
agement under SIOP protocols, and other than for CCSK is not always
helpful in identifying high-risk tumors (both malignant non-WT and
anaplastic WT) and risks misdiagnosis and overtreatment of WT. Fur-
thermore, biopsy is associated with some risks and delaying the start
of chemotherapy. On this basis, we have amended our national clini-
cal guidelines, which follow the SIOP approach, to recommend that no
biopsy is necessary for children aged 6 months–10 years with typical
clinical and imaging presentation for WT. Biopsy should be reserved
for cases where there are clinical or radiographic features to suggest
a non-WT and performed routinely where the child is 10 years or older
under image guidance and using modern coaxial percutaneous cutting
needle biopsy techniques.
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SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
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